Paradigm Health has raised $78 million as it works to revamp the clinical research ecosystem, while also announcing a deal to ...

GE HealthCare and the Mayo Clinic are expanding their long-running collaborative work to now include the development of new personalized radiation therapy approaches for cancer, with a pl | The ...

The FDA has placed a hold on Denali Therapeutics’ plans to launch a phase 1 rare disease trial, citing concerns about immune ...

In 2003, Medtronic first received a humanitarian green light from the FDA to offer its deep brain stimulation implants to ...

In return, Royalty will receive a 9.25% royalty on worldwide sales of tividenofusp alfa from Denali until it reaches three times the amount Royalty has handed to Denali—or, alternatively, 2.5 times ...

Lagging behind the PD-1xVEGF leaders, Crescent has strengthened its hand by licensing Kelun’s integrin beta-6 ...

Almost four years after penning its first amyloidosis collaboration with Neurimmune, AstraZeneca has returned to ...

The FDA has named Tracy Beth Høeg, M.D., Ph.D., as acting director of its Center for Drug Evaluation and Research, continuing ...

The FDA has proposed cutting fees for early-stage companies conducting clinical development in the U.S. instead of abroad. | ...

Hugo is heading to the U.S., with Medtronic finally securing a stateside clearance for its robotic surgery platform. | The ...

A new CRO called Avetra has emerged with a mission of modernizing clinical research operations by prioritizing transparency ...

In 105 boys and young men enrolled in the HOPE-3 trial, patients given deramiocel every three months for a year had 54% ...